Skip to main content

Table 2 Characteristics of subjects used in the study (plasma and serum)

From: RIG-1 receptor expression in the pathology of Alzheimer’s disease

Group Braak stage AD (CERAD) Age at death Gender Apoe PMI (hours)
NCI 0 B = CERAD Probable 92 M 3/5 3.33
NCI 0 No 85 F 3/3 2.50
NCI 1 No 90 F 2/3 4.00
NCI 1 No 100 F 2/3 2.25
NCI 1 No 84 F 3/4 3.00
NCI 1 No 79 F 3/4 1.75
MCI 2 B = CERAD Probable 91 F 3/4 1.75
MCI 2 B = CERAD Probable 93 F 3/4 2.75
MCI 2 B = CERAD Probable 80 F 3/4 2.00
MCI 2 A = CERAD Probable 81 M 3/5 2.83
MCI 2 C = Definite AD 79 M 3/3 1.75
MCI 4 B = CERAD Probable 77 M 3/4 2.75
MCI 3 B = CERAD Probable 92 F 2/3 3.25
AD 6 C = Definite AD 78 M 3/4 3.50
AD 6 C = Definite AD 84 M 3/4 2.75
AD 6 C = Definite AD 83 F 3/3 3.50
AD 6 B = CERAD Probable 85 M 3/3 2.75
AD 6 B = CERAD Probable 80 M 3/3 2.75
AD 6 C = Definite AD 87 M 3/4 3.25
AD 6 C = Definite AD 73 M 3/3 2.00
AD 6 C = Definite AD 80 F 3/3 4.00
AD 6 C = Definite AD 83 F 3/4 2.25
AD 5 C = Definite AD 91 F 3/3 3.00
  1. AD: Alzheimer’s disease, Apoe, apolipoprotein e; CERAD: Consortium to Establish a Registry for AD: MCI: mild cognitive impairment, NCI: no cognitive impairment, PMI: postmortem interval.